Zentiva called an Extraordinary General Meeting (EGM) on 2 April 2007 at 11:00 in Amsterdam to approve the acquisition of majority stake in Eczacibasi. Zentiva agreed to acquire a 75% stake in Eczacibasi Generic Pharmaceuticals for EUR 460m, which is pending the approval of competition offices.
Our view: We consider the acquisition price to be fair and we see a strong strategic rationale for the deal. Thus, we see shareholders are likely to nod on the acquisition plans of Zentiva.